CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- DEF 14A Proxy Proxy Statement
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 4/A Open-market buy 10% owner bought 263,158 shares at $19.00 ($5,000,002)
- 3/A Insider 3/A
- 4 Grant or award Chief Legal Officer acquired 41,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- SC 13D Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 263,158 shares at $19.00 ($5,000,002)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market buy 10% owner bought 2,300,000 shares at $19.00 ($43,700,000)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 3 Insider Initial Statement of Ownership
- 8-K Event Bylaws or fiscal year change
- 4 Open-market buy Director bought 3,947 shares at $19.00 ($74,993)
- 4 Open-market buy Director bought 6,578 shares at $19.00 ($124,982)
- 4 Grant or award Chief Medical Officer acquired 28,333 shares (grant or award)
Page 20 of 23 · 446 filings